50
Participants
Start Date
May 12, 2015
Primary Completion Date
April 4, 2017
Study Completion Date
April 4, 2017
tbo-filgrastim
5 μg/kg
Teva Investigational Site 51186, Budapest
Teva Investigational Site 51185, Budapest
Teva Investigational Site 51184, Szeged
Teva Investigational Site 59105, Varna
Teva Investigational Site 60014, Zagreb
Teva Investigational Site 60016, Zagreb
Teva Investigational Site 12959, Valhalla
Teva Investigational Site 59104, Sofia
Teva Investigational Site 58146, Vinnytsia
Teva Investigational Site 58149, Vinnytsia
Teva Investigational Site 12954, Jackson
Teva Investigational Site 12960, Columbus
Teva Investigational Site 60015, Rijeka
Teva Investigational Site 58147, Kharkiv
Teva Investigational Site 12957, Houston
Teva Investigational Site 58148, Lviv
Teva Investigational Site 12953, Las Vegas
Teva Investigational Site 12951, Los Angeles
Teva Investigational Site 12958, Long Beach
Teva Investigational Site 50284, Moscow
Teva Investigational Site 50280, Saint Petersburg
Teva Investigational Site 52065, Timișoara
Teva Investigational Site 50281, Krasnodar
Teva Investigational Site 52064, Cluj-Napoca, Cluj
Teva Investigational Site 50283, Volgograd
Teva Investigational Site 50282, Chelyabinsk
Teva Investigational Site 53249, Gdansk
Teva Investigational Site 53248, Lublin
Teva Investigational Site 53245, Warsaw
Teva Investigational Site 53246, Warsaw
Teva Investigational Site 53247, Wroclaw
Teva Investigational Site 52063, Bucharest
Teva Investigational Site 58145, Kyiv
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY